Navigation Links
Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Date:12/10/2007

therapy.

Genta has filed a currently pending appeal to the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), which seeks reconsideration of FDA's decision in December 2006 not to approve the use of Genasense in patients with relapsed/refractory CLL.

"The addition of Genasense to chemotherapy has resulted in a clinically meaningful survival benefit for patients who achieved CR," commented Dr. O'Brien. "These data strongly confirm the high degree of clinical benefit that accrues to patients who achieve CR. Achievement of CR remains an essential goal of CLL treatment."

"As one of the patients who remains in CR more than 4 years after receiving Genasense on this study, I strongly support the pending appeal of FDA's decision that declined to make this drug available to other patients who suffer from CLL," commented Thomas F. Mahoney, who entered the Phase 3 Genasense trial in 2002.

Genasense in CLL

In the Phase 3 trial, patients with relapsed or refractory CLL were randomly assigned to receive chemotherapy with fludarabine plus cyclophosphamide (Flu/Cy) with or without Genasense. This study - the only randomized controlled trial ever conducted in this population - achieved its intent-to-treat primary endpoint, which was a statistically significant increase in the proportion of patients who achieved a complete or nodular partial response (CR) (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. In addition, the duration of CR - a prospectively specified and independent secondary endpoint -- was also significantly longer for patients treated with Genasense (median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for patients treated with chemotherapy alone).

The data presented today are exploratory analyses based on extended follow-up of all pat
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2008)...INGAPORE, Aug. 15 /- AstraZ...new partnership with the National Cancer,Centre Si...l (NUH) to,develop anti-cancer compounds. The coll...nderstanding (MOU) that was signed today, aims to ...ilities in Asia and ultimately,speed up access to ...
(Date:8/14/2008)...st T cell engaging antibody (BiTE) showing clinica... patients own T cells to recognize and attack ...Md., Aug. 14 /- Micromet, I...developing novel, proprietary,antibodies for the t...seases, today announced publication of a Phase 1 c...
(Date:8/14/2008)... - Phase 2 development to begin in late 2008 or i...wswire-FirstCall/ -- Nuvelo, Inc.,(Nasdaq: NUVO )...b,proof-of-concept trial of NU172, demonstrating t... and maintained anticoagulation with a rapid,retur...favorable safety,profile., "NU172 has the potenti...
(Date:8/13/2008)...igh Omega-3 Fat Intake Improves Insulin Sensitivit...lter Endocrine Responsiveness, PHOENIX, Aug. 13 /...enix-based Kronos Longevity Research Institute (KL... insulin sensitivity and reduces inflammatory,mark...This study was,recently published in Hormones and ...
Breaking Medicine Technology:AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Study Shows Benefits of a High Omega-3 Diet in Older Adults 2Study Shows Benefits of a High Omega-3 Diet in Older Adults 3Biophysical Society announces winners of 2008 Minority Travel Awards 1714 1Biophysical Society announces winners of 2008 Minority Travel Awards 1714 2Kids in Poor Neighborhoods Fall Behind in School 8726 1Kids in Poor Neighborhoods Fall Behind in School 8726 2Songbirds offer clues to highly practiced motor skills in humans 8724 1Songbirds offer clues to highly practiced motor skills in humans 8724 2Songbirds offer clues to highly practiced motor skills in humans 8724 3Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America 8720 1Gerresheimer Expands its Pharmaceutical Plastic Operations Into Southern Europe and South America 8720 2
.../ -- A new Harris Poll,suggests that the flu vacci...ctive than the vaccines used in some previous year... were only 24 percent,less likely to get the flu t... were larger in two previous Harris Polls on the s.../2005 adults who were,vaccinated were 33 percent a...
...udy showed significant,results in favor of alemtuz...., May 02, 2007,/PRNewswire-FirstCall/ -- Genzyme ...day announced detailed interim results from the,CA... patient data,through at least twenty-four months ...d that a once-yearly cycle of alemtuzumab,treatmen...
Other Medicine Technology:Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 2Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 3Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 4Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 5Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 6Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 7Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 8Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year,Alemtuzumab in Multiple Sclerosis Data Presented at AAN 9
(Date:8/20/2008)...ewswire/ -- Governor Edward,G. Rendell today said ...,with high fuel costs and a broken healthcare syst...ergy independence and make healthcare more,afforda...ed to hear the Governor,s message at the,Governmen...nsylvania,s,largest outdoor agricultural expositio...
(Date:8/20/2008)...art of a new generation of neurosurgeons who are m...At Loyola University Hospital, Duckworth is using ...ir life-threatening aneurysms and to dramatically ...han removing large sections of the skull or face, ...er openings. And in certain cases, he goes through...
(Date:8/20/2008).../ -- Yesterday evening,Congresswoman Stephanie Tu...fering an aneurysm while driving her car in Clevel...Jones, condition has stabilized and she is,receivi...followed a full day of activity, including plannin...uled for September 4, 2008,at Cleveland State Univ...
(Date:8/20/2008)...alth technologies designed to,monitor and care for...s in,excess of $1.8 billion by 2013., Technologic...hardware,revenues, according to Parks Associates, ...ogies. Connected medical, activity, and environmen...ring in more than twice the,dollar amount of the l...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2Health News:Brain surgery is getting easier on patients 2Health News:Brain surgery is getting easier on patients 3Health News:Service and Hardware Revenues Will Contribute $1.8 Billion to the U.S. Eldercare Industry by 2013 2
...ucted by drug researchers has revealed that enabli...ates who are addicted to heroin, //would serve a d...nce and the cost of locking up prisoners for a yea...l Health and Medical Research Council sponsored th...
...ugh a study by neuroscientists at Harvard Medical ...-term exposure to stress hormone in mice directly ...ssion. // April issue of Behavioral Neuroscience, ...chological Association, has this article. This wo...
...es on headline-grabbing diseases, hemophilia, a li...silent killer with over 50,000 people affected. //... to promote a global effort to secure appropriate ...is the oldest known inherited bleeding disorder ca...
...e the promising field of stem cell technology furt...g study //that intends to verify the virtue, succe... a cure for heart disease. Experiments will be c... heart patients. This study will be a fusion of ef...
Other Medicine News:Health News:Cost-Benefit Economics of Methadone for prisoners 2
Heine Beta 200 Streak Retinoscope 3.5v w/Twist Lock for Welch-Allyn style handles.
Heine Beta 200 Streak Retinoscope 3.5v
Video Equipment
Micro-mini fiber optic light.
Medicine Products: